European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-08-01 to 2024-08-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure1002
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci691
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O405
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th225
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology212
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial209
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and201
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial 188
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications180
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology174
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F159
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019150
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy118
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study115
Ultrasound imaging of congestion in heart failure: examinations beyond the heart106
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan105
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care105
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients103
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) 103
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study102
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)102
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology100
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction99
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper96
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure96
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF95
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial91
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF90
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis90
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure87
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection83
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction82
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London82
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC81
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review81
Cachexia, muscle wasting, and frailty in cardiovascular disease80
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies79
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction79
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization77
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart77
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction76
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy75
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction74
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review74
Regional adiposity and heart failure with preserved ejection fraction74
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades73
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients73
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis72
The cancer patient and cardiology70
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology70
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics67
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study67
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje67
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men67
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial67
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure65
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology64
Effect of dapagliflozin on anaemia in DAPA‐HF63
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy62
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist60
0.081234931945801